Research & Development


Technology Platform

  • Target Specific and Long-acting Delivery of Proteins

  • Neutralizing Antibodies Discovery

  • Industrialization of Recombinant Proteins and Antibodies

  • Design of Novel Small-molecule Antivirals

Dr. Tao Wang

The CSO of Beijing Kawin Technology and the CEO of Kawin Biosciences USA

Dr. Wang received B.S. degree in Organic Chemistry from Peking University in 1990 and Ph.D. degree in Organic Chemistry from New York University in 1996.From 1996 to 1998, he was a postdoctoral associate with Professor Gilbert Stork at Columbia University.

From 1998 to 2021, Dr. Wang led the discovery of new antiviral and immune-oncology medicines in Bristol-Myers Squibb, both small molecules and peptides.

Among Dr. Wang’s multiple clinical compounds, RukobiaTM (fostemsavir) was approved by the FDA in July 2020 and by EMA in February 2021.

Dr. Wang is the inventor of 101 filed patent applications, among which 75 have been granted in US. Dr. Wang has co-authored 45 peer-reviewed research articles and 6 reviews. Dr. Wang has been the recipient of several awards from Bristol-Myers Squibb Co., including Chemistry Leadership Award, The President’s Award and Innovation Award.

His current responsibilities in Kawin include: 1) overseeing R&D research center, 2) managing Kawin USA subsidiary, 3) building pipeline, 4) fostering external collaborations, and 5) participating in investing activities.




+86 10 87120888